 "Wockhardt")
A "suspicious package" received on Wednesday at a vaccine production facility of India-headquartered bio-pharmaceutical major Wockhardt in the UK led to a partial evacuation of the site while the local police investigate the matter.
The factory, located at Wrexham Industrial Estate in North Wales, operates a fill-finish production line for the Oxford/AstraZeneca vaccine against COVID-19 after an agreement was struck in August last year.
Local reports suggest that a bomb disposal unit has also been deployed as part of the investigations at the unit.
Wockhardt UK in Wrexham this morning received a suspicious package to site. All relevant authorities were immediately notified and engaged, a Wockhardt UK statement said.
Upon expert advice we have partially evacuated the site pending a full investigation. The safety of our employees and business continuity remain of paramount importance, it said.
The local North Wales Police force said officers remain at the Wrexham Industrial Estate to deal with the incident and that there are no reports of any injuries.
More From This Section
"We are currently dealing with an ongoing incident on the Wrexham Industrial Estate. The roads are currently closed and we would ask the public to avoid the area until further notice," a police statement said.
The Wrexham plant has the capability to produce around 300 million doses of the vaccine a year. The Welsh government stressed that there had been "no adverse effects" on the coronavirus vaccine roll-out as a result of the security alert.
The UK government has reserved one fill-finish production line at Wockhardt UK for its exclusive use for 18 months in order to guarantee the supply of vaccines required to fight against COVID-19, the company had confirmed during a visit by UK Prime Minister Boris Johnson to the Welsh facility last November.
Our agreement with Wockhardt is a significant milestone for the British life science industry and will help produce the vaccines this country needs," Johnson had said at the time.
In the UK, Wockhardt claims to be one of the largest suppliers into the National Health Service (NHS) and has had a presence for over 20 years at Wrexham, where it employs over 400 people at its 612,000 square feet hi-tech manufacturing facility.
Our sophisticated sterile facility and highly skilled workforce are a prime example of why the manufacturing sector is a major employer accounting for around 9 per cent of the UK workforce, said Ravi Limaye, Managing Director of Wockhardt UK, during the prime ministerial visit last year.
The company's "world-class" manufacturing site at Wrexham manufactures a number of sterile injectable products covering a wide range of therapy areas including diabetes, anticoagulation and pain management. The products are available in many forms such as vials, cartridges and ampoules including lyophilised (dry powder) products.
In addition to their own Wockhardt branded products, the firm also provides contract manufacturing services for companies around the world.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
